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AbstrACt
Introduction Severe trauma represents the leading 
cause of mortality worldwide. While 80% of deaths 
occur within the first 24 hours after trauma, 20% occur 
later and are mainly due to healthcare-associated 
infections, including ventilator-associated pneumonia 
(VAP). Preventing underinflation of the tracheal cuff is 
recommended to reduce microaspiration, which plays a 
major role in the pathogenesis of VAP. Automatic devices 
facilitate the regulation of tracheal cuff pressure, and 
their implementation has the potential to reduce VAP. The 
objective of this work is to determine whether continuous 
regulation of tracheal cuff pressure using a pneumatic 
device reduces the incidence of VAP compared with 
intermittent control in severe trauma patients.
Methods and analysis This multicentre randomised 
controlled and open-label trial will include patients 
suffering from severe trauma who are admitted within the 
first 24 hours, who require invasive mechanical ventilation 
to longer than 48 hours. Their tracheal cuff pressure will 
be monitored either once every 8 hours (control group) 
or continuously using a pneumatic device (intervention 
group). The primary end point is the proportion of patients 
that develop VAP in the intensive care unit (ICU) at day 
28. The secondary end points include the proportion of 
patients that develop VAP in the ICU, early (≤7 days) or 
late (>7 days) VAP, time until the first VAP diagnosis, the 
number of ventilator-free days and antibiotic-free days, the 
length of stay in the ICU, the proportion of patients with 
ventilator-associated events and that die during their ICU 
stay.
Ethics and dissemination This protocol has been 
approved by the ethics committee of Poitiers University 
Hospital, and will be carried out according to the 
principles of the Declaration of Helsinki and the Good 
Clinical Practice guidelines. The results of this study 
will be disseminated through presentation at scientific 
conferences and publication in peer-reviewed journals.
trial registration Clinical Trials NCT02534974
IntroduCtIon
Background and rationale
Severe trauma represents the leading cause 
of mortality worldwide, and is the third 
highest cause of death in France behind 
cardiovascular disease and cancer. About 46 
deaths following trauma occur per 1 00 000 
inhabitants per year in France, representing 
strengths and limitations of this study
 ► This study will be conducted as a multicentre 
randomised controlled and open-label trial 
adequately powered to determine whether 
continuous regulation of tracheal cuff pressure 
using a pneumatic device reduces the incidence of 
ventilator-associated pneumonia.
 ► This will be the first large study on that topic with the 
potential of changing international recommendations 
on ventilation-associated pneumonia prevention.
 ► Study’s benefits include reduced duration of 
mechanical ventilation and stay in the intensive care 
unit, improved patient prognosis and reduction in 
antibiotics use.
 ► Limitations due to the lack of masking related to the 
nature of the intervention are limited by a masked 
end point assessment.  on
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close to 8% of all deaths.1 2 While 80% of deaths occur 
within the first 24 hours of trauma, directly related to the 
trauma itself, 20% of deaths occur later and are mainly 
due to healthcare-associated infections (HAI).3–6 More 
than 50% of patients that present with severe trauma will 
develop at least one HAI during their stay. Neurological 
disorders, recourse to mechanical ventilation and early 
post-traumatic immune suppression may explain the 
elevated incidence of HAI, particularly ventilator-associ-
ated pneumonia (VAP), which mainly occur in the first 
week following trauma.7–9
VAP represents the predominant HAI in severe trauma 
patients with a mean incidence of 35%, which may even 
exceed 60% in some series, followed by catheter infec-
tions and bacteraemia.3–6 HAI account for heightened 
morbidity and mortality, longer stays in the intensive care 
unit (ICU) and increased treatment costs. In France, the 
additional cost is estimated at €800 million per year.1 
These infections also require high use of antibiotics, and 
VAP alone makes up more than half of the antibiotic 
treatments prescribed in the ICU.7 Given the selection 
pressure they induce, these antibiotic therapies favour 
the appearance of bacterial resistance.
VAP pathophysiology
The presence of a foreign material (tracheal tube or 
stomach tube) facilitates colonisation of the upper 
airways and digestive tract by endogenous and exog-
enous microorganisms. Tracheal contamination 
originates through bacterial aspiration, resulting from 
the passage of secretions from around the cuff of the 
tracheal tube accumulating above the tracheal cuff.10 
More rarely, VAP can arise from contaminated stagnant 
water in the ventilator circuit, use of colonised aerosols 
or a contaminated contiguous site (almost exclusively 
the pleural cavity).11
Prevention measures for VAP
Enhanced knowledge of the pathophysiology of VAP 
has led to the development of effective preventive strat-
egies. The VAP prevention measures recommended by 
the 2008 French consensus conference on nosocomial 
infection prevention12 state that the orotracheal route 
should be used for tracheal intubation instead of the 
nasal route,7 11 13 and the tracheal cuff pressure should 
be maintained between 25 and 30 cm H2O.
14 15 They 
also recommend using a sedation-analgesia algorithm 
that facilitates early weaning off ventilation, avoid-
ance of unplanned extubation,16 prioritising the use 
of non-invasive ventilation by following the recognised 
indications,16 17 placing the patient in a semi-recumbent 
position between 30° and 45°,18 19 regularly decontam-
inating the nasal and oropharyngeal cavity through 
suitable mouth care20 21 and starting enteral nutrition as 
early as possible.22 When combined with systemic antibi-
otic therapy, selective digestive decontamination may be 
recommended, but its implementation requires specifica-
tion of its modalities (choice, dosing, duration of selective 
digestive decontamination and antibiotic therapy) and 
the targeted population.
Maintaining a sufficient level of pressure in the tracheal 
tube cuff is of critical importance. When the pressure is too 
low, the patient risks inhaling the accumulated subglottic 
secretions from the oropharynx, which is known to play 
a major role in VAP incidence.14 15 Alternatively, if the 
pressure is too high there is a risk of ischaemia of the 
tracheal mucosa and, at removal, of tracheal oedema and 
later tracheal stenosis. Therefore, regular monitoring of 
tracheal cuff pressure is recommended, but the optimal 
monitoring frequency has yet to be clearly determined. 
Underinflation and/or overinflation of the tracheal 
cuff often occurs in ventilated patients under intermit-
tent manual control of tracheal cuff pressure using a 
manometer, which is a well-known source of morbidity 
and mortality.23 Recently published data favour use of 
automatic devices that are able to continuously regu-
late the tracheal cuff pressure.24–31 Even though several 
learned societies do not recommend their implemen-
tation for the purpose of VAP prevention in ventilated 
patients, recent findings in the literature tend to favour 
their use.24 25 27 29 32 However, these studies have several 
limitations, as all were monocentre studies that included 
a relatively small number of participants, which rarely 
included severe trauma patients even though they are at 
greatest risk for VAP, and these studies did not systemati-
cally apply other recommended VAP preventive measures, 
with a contestable choice for the main study end point.
Two methods of continuous regulation of tracheal 
cuff pressure are available: pneumatic and electronic. 
Published studies favour the first33 due to better reactivity 
with fewer periods of insufficient or excessive tracheal 
cuff pressure, and consequently, reduced risk of microbe 
inhalation and tracheal injuries, in addition to the low 
acquisition cost, ease of use and no electricity supply 
required.
objectives
The objective of this study is to determine whether 
continuous regulation of tracheal cuff pressure using a 
mechanical pneumatic regulation device (Nosten, Leved, 
Paris) is superior to intermittent control of tracheal cuff 
pressure for reducing the incidence of VAP in severe 
trauma patients, who will receive all other recommended 
methods of VAP prevention. At an individual level, the 
benefits are expected to include a shorter duration of 
mechanical ventilation and stay in the ICU, as well as 
improved patient outcomes. At a collective level, in addi-
tion to reduced cost of hospital stay, the number of days 
on antibiotics should also decline, along with the selective 
pressure perpetuating the emergence of multidrug-resis-
tant bacteria.
study design
The AGATE trial is a multicentre randomised controlled 
and open-label clinical trial with two parallel groups, 
with the primary end point being the proportion of 
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patients that develop VAP in the ICU at day 28. Rando-
misation will be carried out through a secure web-based 
randomisation system, stratified by the centre and severity 
of patient unconsciousness at the time of inclusion 
(Glasgow Coma Scale lower and higher or equal to 8).
MEthods And AnAlysIs
Participants
Patients will be considered candidates for inclusion in 
the study if they meet all of the inclusion criteria and 
none of the exclusion criteria (box 1). Patients suffering 
from severe trauma admitted within the first 24 hours, 
who require invasive mechanical ventilation expected 
to last longer than 48 hours, should be included in the 
study. For all cases, patient inclusion will take place as 
soon as possible after ICU admission, during the 24 hours 
following trauma and/or over the 15 hours following oral 
intubation of the trachea. Pregnant or lactating women 
can be included in the study because the material used 
does not present any specific risk of teratogenicity.
Interventions
All of the patients included in the study will be randomised 
in one of the two treatment groups, which are based on 
the method used to monitor tracheal cuff pressure and 
benefit from daily monitoring throughout their hospital 
stay in the ICU. The following criteria will be applied to 
all patients and controlled throughout the duration of 
the study.
 ► Monitoring of tracheal cuff pressure of the tracheal 
tube either once every 8 hours in the control group or 
continuously in the intervention group through the 
use of a pneumatic device (Nosten), with the objective 
of maintaining pressure between 25 and 30 cm H2O.
 ► Implementation of identical sedation and weaning 
protocols for all centres.
 ► Implementation of a lung protective ventilation strat-
egy34 by maintaining a tidal volume of 6–8 mL/kg of 
ideal body weight, positive end-expiratory pressure >3 
cm H2O and respiratory rate set to achieve normocap-
nia or optional moderate hypocapnia.
 ► According to the protocol observed in the unit, ex-
tubation should be considered as soon as: (1) the 
patient’s Glasgow Coma Scale is >10; (2) the patient 
is coughing spontaneously or secondary to bron-
chial aspiration and (3) the level of pressure sup-
port is <10 cm H2O, or spontaneous ventilation on a 
T-piece with FiO2 lower than 40% is tolerated by the 
patient for at least 30 min.
 ► No systematic changes to the respirator circuits.
 ► Preferential use of heat and humidity exchange filters 
to be changed only when soiled.
 ► Systematic application of bed inclination of at least 
30° to be monitored every 4 hours.
 ► Hand washing (hydroalcoholic friction) prior to any 
treatment and following isolation measures.
 ► Mouth care every 4–8 hours according to the protocol 
observed in the unit.
 ► Tracheal aspiration carried out using sterile equip-
ment, only to be performed when required.
 ► Preferential oral insertion of feeding tubes.
 ► Starting enteral feeding as soon as possible.
 ► Systematic application of a glucose monitoring pro-
tocol in which the patient’s blood sugar level is meas-
ured every 4 hours, the objective being to maintain 
the glucose level between 4 and 8 mmol/L.
 ► Prophylactic antibiotic treatment limited to 48 hours 
for fractures operated within the first 6 hours.
 ► Curative antibiotic therapy reserved for infections for 
which the bacterial origin is documented, or proba-
ble, and in cases where other anti-infectious measures 
are insufficient, in accordance with the 2008 recom-
mendations of the official French health authority on 
the proper use of antibiotics.35 An adequate dosage 
regimen and method of antibiotic administration is 
provided to ensure an optimal concentration at the 
site of infection. Recourse to serum assay is useful 
whenever possible to avoid underdosing, which is 
a common cause of failure, as well as to avoid over-
dosing, which leads to iatrogenic pathologies. Nar-
row-spectrum antibiotics are preferred. In cases of se-
vere infection, antibiotic treatment should be started 
as soon as possible following diagnostics and microbi-
ological sampling, and started no later than the first 
hour in cases of septic shock. The duration of VAP 
treatment should be limited to 1 week, except in cases 
with non-fermenting Gram-negative bacterial infec-
tions for which antibiotic therapy should continue for 
2 weeks to reduce the risk of recurrence. Antibiotic 
associations are strictly limited to precisely defined 
box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Patients aged at least 18 years
2. Suffering from a severe trauma as defined by an Injury Severity 
Score >15
3. With their tracheal intubated via the oral route for <15 hours
4. Requiring mechanical ventilation for an expected length ≥48 hours.
5. Participating in a social security scheme or benefiting from such a 
scheme by means of a third party
Exclusion criteria
1. Patient likely to die in the 48 hours following admission
2. Having their trachea intubated via the nasal route
3. Patient intubated through a tracheal tube with subglottic secretion 
drainage
4. Having their trachea intubated 24 hours or more after trauma
5. Being ventilated with tracheotomy
6. Refusing to participate in the research
7. Having contraindication to the head-up position
8. Participating in another research protocol pertaining to an anti-in-
fective treatment or to a measure decreasing risk of infection
9. Benefiting from reinforced protection or persons deprived of free-
dom subsequent to a legal or administrative decision, majors under 
legal protection
 o
n
 7 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017003 on 7 August 2017. Downloaded from 
4 Marjanovic N, et al. BMJ Open 2017;7:e017003. doi:10.1136/bmjopen-2017-017003
Open Access 
situations: the need to broaden the antibacterial spec-
trum; severe and microbiologically undocumented 
infections; Pseudomonas aeruginosa infections and 
bacteria and antibiotic combinations associated with 
a high risk of resistance emergence. These include 
group 3 Enterobacteriaceae (eg, Enterobacter, Serratia, 
Citrobacter freundii, Providencia and Morganella) and 
third-generation cephalosporins; Staphylococcus aureus 
and fluoroquinolones, rifampicin, fusidic acid or fos-
fomycin and Enterobacteriaceae resistant to nalidixic 
acid and fluoroquinolones. Antibiotic therapy should 
be re-evaluated between 24 and 72 hours.
 ► Prevention of ulcer disease by anti-H2 and proton 
pump inhibitors, in accordance with the protocol ob-
served in the centre.
Study outcomes
Primary end point
 ►  Proportion of patients that develop VAP at day 28 in 
the ICU according to the American Thoracic Society 
(ATS) definition (box 2).7
Secondary end points
 ► Proportion of patients that develop VAP in the ICU 
according to the ATS definition.7
 ► Proportion of patients that develop bacteraemic VAP 
in the ICU according to the ATS definition. Bacter-
aemic VAP is defined as at least one positive blood 
culture that is not related to any other source of in-
fection, and at least one positive respiratory sample 
culture obtained within 48 hours of each other. In ad-
dition, at least one of the microorganisms isolated in 
the respiratory sample needs to also be isolated in the 
blood cultures, whereas all isolates identified in the 
blood cultures (except for skin contaminants) should 
also grow in the simultaneously obtained respiratory 
sample in order to meet the complete definition of 
bacteraemic pneumonia.
 ► Proportion of patients that develop early (≤7 days) or 
late (>7 days) VAP in the ICU according to the ATS 
definition.7
 ► Time until the first diagnosis of VAP according to the 
ATS definition.7
 ► Proportion of patients that develop ventilator-associ-
ated events (VAE) according to the Centers for Dis-
ease Control and Prevention (CDC) definition (ta-
ble 1).36
 ► Number of ventilator-free days.
 ► Number of antibiotic-free days.
 ► Length of stay in the ICU.
 ► Proportion of patients that die during their ICU stay.
 ► Proportion of patients that require corticosteroids or 
bronchodilators within 48 hours of tracheal extuba-
tion.
Attempted detection of VAP signs will be performed on 
a daily basis while the patient is being mechanically venti-
lated, in accordance with the definition established by the 
ATS in 2005 (box 2).7 A thoracic X-ray aimed at detecting 
VAP is to be carried out within a few hours whenever at 
least two of the following clinical signs of VAP are observed 
in the same clinical examination: fever ≥38.0°C or hypo-
thermia ≤36.0°C, purulent endotracheal secretions or 
either hyperleucocytosis (≥12 000/mL) or leucopenia 
(≤4000/mL).
Whenever the patient meets the clinical and radiolog-
ical criteria on the same day, VAP is suspected and the 
modified clinical pulmonary infection score will be calcu-
lated, as presented in table 2. Bacterial analysis of the 
respiratory tract will be carried out especially if the calcu-
lated score is >6. The type of sampling (bronchoalveolar 
lavage, blind distal sampling or tracheal aspirates) is left 
to the discretion of the attending physician, and depends 
on the procedures of the unit.
When a patient is suspected to have developed VAP, two 
assessors masked to the group assignment will review the 
case-report form and classify the case according to the 
accepted definition.
Participant timeline
The patients will be monitored from randomisation 
through to their discharge from the ICU without 
exceeding 60 days following inclusion. Evaluation of the 
assessment criteria will be carried out depending on the 
duration of patient stay in the ICU.
 ► Evaluation will be carried out on discharge from the 
ICU for patients with an ICU stay of <28 days.
 ► Evaluations will be carried out on day 28 and on dis-
charge from the ICU for patients with an ICU stay of 
≥28 but <60 days.
 ► Evaluations will be carried out on days 28 and 60 for 
patients with an ICU stay of ≥60 days.
Any patient who leaves the ICU will be considered 
to have exited the study. Any readmission into the ICU 
(even within 60 days following the trauma) will not be 
taken into account. Any event that occurs after the first 
box 2 American thoracic society definition for VAP
VAP diagnosis is based on an association, 48 hours after the start of 
mechanical ventilation, of at least:
Two clinical signs among the following:
 ► Fever ≥38.0°C or hypothermia ≤36.0°C
 ► Purulent endotracheal aspirations
 ► Hyperleucocytosis (≥12 000/mL) or leucopenia (≤4000/mL)
One radiological sign such as:
 ► A new radiographic condensation
 ► Modification of a previously existing radiographic condensation
And a positive bacterial analysis of the respiratory tract with cultures 
of at least:
 ► 103 CFU/mL for a brush by fibroscopy or blind protected distal 
sampling
 ► 104 CFU/mL for bronchoalveolar lavage
 ► 106 CFU/mL for tracheal aspirates
CFU, colony-forming unit; VAP, ventilator-associated pneumonia.
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ICU discharge will not be considered in the assessment 
criteria.
Any patient can exit the study if he or she wishes, 
without having to provide justification. The quality of 
their care will not be altered, and the outcome will not be 
taken into account in the final analysis.
sample size calculation
The number of participants (n=220 in each group) is 
based on an estimation of VAP incidence of 20% of 
patients in the control group and a reduced VAP inci-
dence (halved) in the intervention group, with a study 
power of 80% and p value of 5% in bilateral situation. 
The VAP incidence in the control group was chosen on 
the basis of an unpublished analysis of the database of 
AtlanRéa, a French research network devoted to studies 
on trauma patients.37 38
Given the recruitment potential of the centres 
approached to participate in the study, together with the 
constraints associated with the protocol, the expected 
inclusion duration has been set at 33 months.
recruitment
Patients admitted into the ICUs of 15 French University 
Hospitals will be screened and enrolled within 24 hours 
of trauma. Patient enrolment will be decided by the 
attending physicians.
Assignment of interventions and masking protocol
A computer-generated numbered list was provided by 
a statistician not involved in either screening patients 
or the assessment of outcomes. Randomisation will be 
carried out using a secure web-based randomisation 
system with stratification by centre and severity of uncon-
sciousness at the time of inclusion (Glasgow Coma Scale 
<8 or ≥8), to account for differences in patient treat-
ment between centres and the heightened VAP risk in 
patients with a Glasgow Coma Scale <8. Patients will be 
randomly assigned (1:1) into one of the two treatment 
groups, based on the method used to monitor tracheal 
cuff pressure. Masking of the participants and ICU staff 
will not be feasible due to the nature of the device, which 
is placed closed to the patient’s face. However, the micro-
biologists that test the pulmonary and blood samples, the 
outcome assessors (NM and OM) and the statisticians will 
be masked to the group assignment.
data collection, confidentiality, storage and archiving of study 
documents
Independent clinical research assistants are available 
at each participating hospital to help with running 
the study and data collection. Study documents will be 
de-identified and stored for 15 years, as per the protocol 
for non-clinical trial notification (CTN) interventional 
studies. Data will be electronically stored on double pass-
word-protected computers. Hard copies of data (clinical 
research files) will be stored in a locked, secure office. All 
personnel involved in data analysis will be masked. Only 
the principal investigators and the statisticians will have 
access to the final data set.
statistical methods
Analyses will be performed following the intention-to-
treat principle (all randomised patients except those 
that withdrew consent). Statistical analyses will take into 
account the stratified randomisation (centre and Glasgow 
Coma Scale <8 or ≥8), as recommended in the 2010 
Consolidated Standards of Reporting Trials (CONSORT) 
guidelines and other studies reported in the literature.39 40
The categorical variables will be reported as numbers 
and percentages, while continuous variables will be 
summarised using means (±SD) or medians (IQR) for 
normally and non-normally distributed data, along with 
their respective 95% CIs.
Analyses of the primary end point and secondary 
end points related to VAP incidence will use logistic 
regression models adjusted for stratification factors and 
covariates significantly imbalanced between groups.
The cumulative event curves (time until first VAP 
diagnosis) will be estimated using the Kaplan-Meier 
procedure.
The number of ventilator-free days (VFD) is the number 
of days for which the patient is successfully weaned from 
mechanical ventilation until the end point at day 28 (or 
day 60). This is defined as follows: VFD=0 for patients 
who died within 28 (or 60) days or required mechanical 
Table 2 The modified clinical pulmonary infection score for 
ventilator-associated pneumonia7 ARDS, acute respiratory 
distress syndrome.
Temperature (°C)
  ≥36.5 and ≤38.4 0
  ≥38.5 and ≤38.9 1
  ≥39.0 or ≤36.0 2
Leucocytes (g/L)
  ≥4 and ≤11 0
  <4 or >11 1
Tracheal secretion quantity
  Low 0
  Moderate 1
  Abundant 2
Tracheal secretion aspect
  Purulent +1
PaO2/FiO2
  >240 or ARDS 0
  ≤240 and absence of ARDS 2
Frontal chest radiograph
  No infiltrate 0
  Diffuse and/or heterogeneous infiltrates 1
  Localised infiltrate 2
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ventilation for 28 (or 60) or more days; VFDs=(28 (or 
60)−x) for patients who were successfully weaned off 
mechanical ventilation within 28 (or 60) days, where x is 
the number of days on mechanical ventilation.
The number of antibiotic-free days (AFD) is the number 
of days that the living patient did not receive antibiotics 
over 28 (or 60) days. Any prophylactic or curative antibi-
otic therapy related to the trauma will not be considered.
The VFD and AFD will be assessed in the same manner, 
and will be compared between groups using regression 
models that allow adjustment for stratification factors. 
The other categorical secondary end points will be 
compared between groups using logistic regression 
models. Statistical analyses will all be conducted using 
SAS V.9.3 software.
Missing data will be described as the number and corre-
sponding percentage for each group. The presence of 
any imbalance in the proportion of missing data between 
treatment groups will be evaluated using logistic regres-
sion models. To assess the robustness of the results in the 
case of missing data, sensitivity analyses will be performed 
with imputation of missing data (worst value such as 
failure, death, etc) and multiple imputation.
Monitoring
Clinical research associates will ensure that patient inclu-
sion, data collection, registry and rapport are in line 
with the protocol, and that the study is conducted in 
accordance with the Good Clinical Practice guidelines. 
Furthermore, he or she will verify the following vari-
ables: patient initials, date of birth, sex, signed consent 
form, eligibility criteria, date of randomisation, treatment 
assignment, adverse events and study end points.
EthICs And dIssEMInAtIon
Research ethics approval
The clinical trial will be carried out in line with the prin-
ciples of the Declaration of Helsinki and according to the 
Clinical Trials Directive 2001/20/EC of the European 
Parliament on the approximation of the laws, regula-
tions and administrative provisions of the Member States 
relating to the implementation of Good Clinical Practices 
in the conduct of clinical trials on medicinal products 
for human use. Ethical aspects of this research project 
have been approved by the ethics committee of Poitiers 
University Hospital (France). The ethics committee of 
Poitiers approval cover all participant sites. The trial 
will be monitored by the research monitoring officer of 
Poitiers University Hospital.
Consent
Prior consent of the subject will not be possible; therefore, 
consent of the subject’s legally acceptable representative 
will be requested. A consent form specifically designed 
for the subject’s legally acceptable representative will 
be provided with documented approval or favourable 
opinion of the institutional review board in order to 
protect the rights, safety and well-being of the subject 
and to ensure compliance with any applicable regulatory 
requirements. Non-objection to participation in the study 
by the patient’s relatives will be solicited, according to the 
requirements of the ethics committee.
Confidentiality
People with direct access to the data will take all necessary 
precautions to maintain confidentiality. All data collected 
during the study will be rendered anonymous. Only 
initials and inclusion number will be registered.
dissemination policy
The results of the study will be released to the partic-
ipating physicians, referring physicians and medical 
community no later than 1 year after the completion of 
the trial, through presentation at scientific conferences 
and publication in peer-reviewed journals
dIsCussIon
To the best of our knowledge, this is the first large-scale 
study to evaluate the usefulness of continuous pneumatic 
regulation of tracheal cuff pressure in a population of 
severe trauma patients, who will also benefit from other 
recommended VAP preventive measures. At an individual 
level, the benefits are expected to include reduced dura-
tion of mechanical ventilation and stay in the ICU, as 
well as improved patient prognosis. At a collective level, 
a lower cost of hospital stay is expected, in addition to 
fewer days on antibiotics, associated with a reduction in 
the selective pressure perpetuating multidrug-resistant 
bacteria.
In order to keep management practices as standardised 
as possible, we decided to limit the number of investi-
gating centres to 15 university hospital centres (CHU), 
all of which are recognised in the field of trauma care 
and treat more than 50 severe trauma patients per year. 
These centres belong to three networks that share the 
common objective of promoting multicentre clinical 
research, consisting of AtlanRéa (Grand Ouest surgical 
intensive care network), AzuRéa (Grand Sud intensive 
care network) and TraumaBase (APHP trauma intensive 
care network). These 15 centres also share the same stan-
dards of care.
Previous studies that have evaluated devices aimed 
to continuously regulate tracheal cuff pressure have 
reported that these devices are efficient in controlling 
cuff pressure,41 and are well-tolerated by patients.33 In 
this setting, the choice of a pneumatic device instead of 
an electronic device presents several advantages33: better 
reactivity with fewer periods of insufficient or excessive 
pressure into the tracheal cuff, and consequently, reduced 
risk of microinhalations and tracheal lesions; no need for 
an electricity supply; low acquisition cost and ease of use. 
Finally, the encouraging preliminary results previously 
reported using this device also significantly contributed 
to our choice.27
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In the present study, no additional risk will be incurred 
by the study participants in terms of the usual therapy 
received during their hospital stay. Patients will be cared for 
as usual by their attending physicians. No supplementary 
examination will be imposed by the protocol. As the patient 
will be unable to hear the given information, information 
regarding the study will be delivered to his or her close 
relatives or friends. In accordance with the directives of the 
French national commission for data protection and liber-
ties, the patient will be afforded the possibility of objecting 
to the use of data gathered in his or her name.
study limitations
The incidence of VAP is the primary end point of this trial; 
however, VAP diagnosis may be difficult to perform in 
the ICU. Several criteria have been proposed,7 36 42–44 but 
their reported performances are poor.45 In this trial, VAP 
incidence will be determined according to the 2005 ATS 
criteria.7 This choice could be challenged; however, these 
criteria have been commonly used for VAP diagnosis in the 
literature. We will also record VAE according to the CDC 
criteria,36 and compare the ATS and CDC definitions for 
VAP as a secondary objective. The halving of VAP rate could 
seems ambitious for a single intervention. However, such a 
finding was reported in two previous studies assessing the 
clinical impact of continuous control device of cuff pres-
sure.46 47
Because, mouth care and stress ulcer prophylaxis are 
based on local written protocols, they may act as potential 
confounding variables. However, this will be controlled by 
the stratification of the randomisation at the centre level 
and adjustment of statistical analyses in cases of differences 
between groups.
Finally, masking is not feasible due to the nature of the 
intervention. However, the end points will be assessed by 
two assessors masked to the group assignment in order to 
minimise bias.
In conclusion, this trial is the first multicentre 
randomised controlled open-label study adequately 
powered to test the hypothesis that a continuous pneu-
matic regulation of tracheal cuff pressure prevents VAP in 
mechanically ventilated severe trauma patients.
Participating centres
University Hospital of Poitiers (Professor Olivier Mimoz), 
University Hospital of Angers (Professor Sigismond 
Lasocki), University Hospital of Beaujon (Professor Cath-
erine Paugam), University Hospital of Bicêtre (Professor 
Jacques Durnteau), University Hospital of Clermont-Fer-
rand (Professor Jean-Michel Constantin), University 
Hospital of Grenoble (Professor Jean-François Payen), 
University Hospital of Marseille (Professor Marc Leone), 
University Hospital of Nantes (Professor Karim Aseh-
noune), University Hospital of Nice (Professor Carole 
Ichai), University Hospital of Nîmes (Professor Jean-Yves 
Lefrant), University Hospital of Rouen (Professor Benoit 
Veber), University Hospital of Strasbourg (Professor 
Julien Pottecher), University Hospital of Besançon 
(Professor Sébastien Pili-Floury), University Hospital of 
Dijon (Professor Belaid Bouhemad), University Hospital 
of Nancy (Professor Gérard Audibert); all in France.
trial status
The trial is currently in progress, and the inclusion 
process started in July 2015. At the time of manuscript 
submission, 229 patients had been included. The first 
patient was included 2 days after registration of the study 
on  ClinicalTrials. gov. We estimate that the last patient will 
be recruited in January 2018.
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